Full Breakdown
Metformin’s Primary Action Occurs in the Gut, Not the Liver, New Northwestern Study Shows
5/13/2026, 4:05:12 AM
Gut-Centric Mechanism Overturns Decades-Old Liver View
Northwestern researchers led by Navdeep Chandel showed that metformin lowers blood glucose in mice primarily by inhibiting mitochondrial complex I in intestinal epithelial cells, converting the gut into a glucose-absorbing sink, rather than acting on the liver.
Prior Liver-Centric Paradigm
For decades, metformin’s benefit was attributed to suppressed hepatic glucose production, based on early isotope-tracing studies; however, drug concentrations in the liver are far lower than in the intestine.
Study Design, Mouse Model, and Core Findings
The team measured intestinal metformin levels at millimolar concentrations—10-100 × liver and up to 300 × plasma—and engineered mice to express the yeast NDI1 enzyme in gut cells, which bypasses complex I. In these mice, metformin’s glucose-lowering effect was markedly reduced, confirming intestinal complex I inhibition as essential. The findings, published in *Nature Metabolism*, were supported by NIH, the National Heart, Lung, and Blood Institute, and several Northwestern fellowships.
Metabolic Consequences: Glucose Sponge, GDF15, Citrulline
Inhibition of complex I forces gut cells to rely on glycolysis, turning the intestine into a metabolic sponge that extracts post-prandial glucose. The energy stress raises circulating GDF15, a hormone that suppresses appetite, and lowers citrulline, a precursor to nitric-oxide.
Implications for Therapy and Drug Development
The authors propose that gut-targeted drug design could replicate metformin’s efficacy while minimizing systemic exposure, and they note that taking metformin with meals aligns peak intestinal concentrations with post-meal glucose spikes, enhancing its effect.
Criticism, Limitations, and Open Questions
The work is limited to mice; human absorption may differ, and incomplete protection by NDI1 suggests additional targets, possibly the microbiome. Although berberine shares the same gut complex I inhibition, its clinical equivalence to metformin remains unproven.
Verbatim Quotes
- “Metformin essentially helps the intestine suck the glucose out of the bloodstream, which further highlights that the gut plays a major role in regulating blood sugar levels,” — Navdeep Chandel, Northwestern University
- “Metformin has decades of clinical evidence behind it, whereas supplements like berberine are far less rigorously tested,” — Navdeep Chandel
- “If you're going to use berberine, you may as well use the real deal.” — Navdeep Chandel
- “People have always wondered how one drug can do 10 things,” Chandel said. “Well, it can do that if the drug is hitting a big node in a cell, and hitting mitochondria in a cell is a big node. So, if you can get into those cells and inhibit mitochondria, it's going to have huge effects.” — Navdeep Chandel
What’s Next: Human Trials and Gut-Targeted Compounds
The group will initiate human trials to test meal-timed dosing that maximizes gut exposure and will explore gut-restricted compounds, including potential citrulline supplementation to offset exercise-related effects.
